首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   5篇
  免费   0篇
综合类   2篇
畜牧兽医   3篇
  2007年   1篇
  2004年   1篇
  1997年   1篇
  1996年   1篇
  1989年   1篇
排序方式: 共有5条查询结果,搜索用时 171 毫秒
1
1.
An iron-sulfur compound (Fe3S2) was synthesized at pressures greater than 14 gigapascals in the system Fe-FeS. The formation of Fe3S2 changed the melting relations from a simple binary eutectic system to a binary system with an intermediate compound that melted incongruently. The eutectic temperature in the system at 14 gigapascals was about 400°C lower than that extrapolated from Usselman's data, implying that previous thermal models of Fe-rich planetary cores could overestimate core temperature. If it is found in a meteorite, the Fe3S2 phase could also be used to infer the minimum size of a parent body.  相似文献   
2.
3.
BACKGROUND: Hemangiosarcoma (HSA) is a highly metastatic and often rapidly fatal tumor of dogs. At present, adjuvant chemotherapy is the only proven effective treatment for dogs with HSA, though the benefits from chemotherapy are modest. Administration of immunotherapy together with chemotherapy has also been reported to improve survival in dogs with HSA. Therefore, we evaluated safety and immunologic responses to a novel tumor vaccine administered together with doxorubicin chemotherapy in dogs with different stages of HSA. HYPOTHESIS: That tumor vaccination could be safely and effectively combined with doxorubicin chemotherapy for treatment of dogs with HSA. ANIMALS: Twenty-eight dogs with various stages of HSA were enrolled in the study. METHODS: The HSA vaccine was prepared with lysates of allogeneic canine HSA cell lines mixed with an adjuvant composed of liposome-DNA complexes. Dogs received a series of 8 immunizations administered over a 22-week period, and most also received chemotherapy. Clinical adverse effects were noted, immune responses were measured by enzyme-linked immunosorbent assay (ELISA) and flow cytometry, and survival times were calculated. RESULTS: The most common adverse effects observed in vaccinated dogs also treated with doxorubicin chemotherapy were diarrhea and anorexia. Vaccinated dogs were found to mount strong humoral immune responses against a control antigen and, most dogs also mounted antibody responses against canine HSA cells. Thirteen dogs with stage II splenic HSA that received the tumor vaccine plus doxorubicin chemotherapy had an overall median survival time of 182 days. CONCLUSIONS: We conclude that an allogeneic tumor lysate vaccine is safe in dogs with HSA and can elicit humoral immune responses in dogs that are receiving concurrent doxorubicin chemotherapy.  相似文献   
4.
Recent syntheses of high-pressure alkali and alkaline earth silicates reveal a class of framework structures with corner-linked 4- and 6-coordinated silicon. These compounds possess the structural formula (A4-2x1+Bx2+)SimVI(SinIVO2(m+n)+2), where x, m, and n specify the amounts of alkaline earth, 6-coordinated silicon, and 4-coordinated silicon, respectively. Appropriate values of m and n yield a range of high-pressure structures, from fully 4-coordinated to fully 6-coordinated silicate frameworks. Recognition of this class of framework silicates leads to predictions of high-pressure structures as well as room-pressure isomorphs of high-pressure silicates.  相似文献   
5.
Two groups of 4 Hereford steers were housed in a controlled environment room and exposed to simulated high summer temperatures. Both groups were fed a barley grain and hay diet ad libitum. The barley in one diet contained 0.5% w/w ergots of Claviceps purpurea. Within one week of feeding the ergot diet mean rectal temperature was significantly elevated (P less than 0.05) each afternoon (up to 41 degrees C) but returned to normal overnight. Elevated rectal temperature was accompanied by other signs of heat stress, reduced feed intake, body weight loss and depression or serum prolactin concentration. Symptoms disappeared within 1 week of ceasing to feed the ergot diet.  相似文献   
1
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号